title: Nanofiber-coated drug eluting stent for the stabilization of mast cells.
abstract: OBJECTIVE
  The nanofiber-hydrogel blend containing nitric oxide (NO) donors and reactive oxygen species (ROS) scavengers (Edaravone: EDV) was explored as an advanced strategy for stabilization of Mast cells (MCs) to achieve efficient immune-suppressive effects.
  
  
  METHODS
  Three types of nanofiber hydrogel composites (Bare-Nanofibers (BNF), Nanofiber-Hydrogels (NF-Gel) and Cross-linked Nanofiber-Hydrogels (NF-Gel-X)), were evaluated. The degranulation rates of MCs were determined by measurement of the extracellular levels of hydrogen peroxide and the released amounts of β-hexosaminidase from the activated-MCs (a-MCs). In addition, the effects of EDV on the selective scavenging of the oxygen radicals and prevention of peroxynitrite formation were evaluated. The roles of a-MCs in re-endothelialization and viability of coronary artery endothelial cells (hPCAECs) were defined using alamar blue and LDH assay, respectively.
  
  
  RESULTS
  Each polymer matrix has unique morphological characteristics. The effects of EDV (~1.0 mM) on the production of NO were greatly influenced by the presence of superoxide or hydroxyl radicals. NF-G-X containing a mixture of EDV and S-Nitroglutathione (GSNO) produced the highest level of NO under the oxidative stress conditions. GSNO alone or a mixture of GSNO and EDV significantly lowered the degranulation rate of a-MCs (GSNO only: 55.8 ± 5.4%; GSNO with EDV: 50.6 ± 0.6%), indicating that NO plays an integral role in degranulation of a-MCs. There were no significant biochemical evidences of cytotoxic effects of GSNO and EDV on the hPCAECs.
  
  
  CONCLUSIONS
  Nanofibers containing a mixture of nitric oxide donors and ROS scavengers could be used as a promising strategy to stabilize MCs from the ROS-mediated immune responses.
authors.affiliation: Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, HSB-4242, Kansas City, Missouri, 64108, USA.
authors.forename: Byeongtaek
authors.initials: B
authors.lastname: Oh
authors.forename: Chi H
authors.initials: CH
authors.lastname: Lee
mesh_terms: D000983:Antipyrine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D015550:Cell Degranulation / Q000187:drug effects; D002460:Cell Line; D016503:Drug Delivery Systems; D054855:Drug-Eluting Stents; D000077553:Edaravone; D016166:Free Radical Scavengers / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D008407:Mast Cells / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D057139:Nanofibers / Q000737:chemistry*; D020030:Nitric Oxide Donors / Q000008:administration & dosage* / Q000494:pharmacology; D017382:Reactive Oxygen Species / Q000276:immunology
chemical_list: D016166:Free Radical Scavengers; D020030:Nitric Oxide Donors; D017382:Reactive Oxygen Species; D000077553:Edaravone; D000983:Antipyrine